Salvatore De Vita

Udine, Italy

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 235 publications

Identification of new overlapping and disease-specific genetic risk factors for rheumatoid arthritis and radiographic axial spondyloarthritis: a meta-analysis of three large European populations and functional characterization.

Identification of new overlapping and disease-specific genetic risk factors for rheumatoid arthritis and radiographic axial spondyloarthritis: a meta-analysis of three large European populations and functional characterization.

Journal: Frontiers in immunology

Published: May 29, 2025

2023 International Rome consensus for the nomenclature of Sjögren disease.

2023 International Rome consensus for the nomenclature of Sjögren disease.

Journal: Nature reviews. Rheumatology

Published: May 08, 2025

Identification of novel autoantibodies in Sjögren's disease.

Identification of novel autoantibodies in Sjögren's disease.

Journal: Frontiers in immunology

Published: November 08, 2024

Transition-related outcomes among a cohort of patients with juvenile idiopathic arthritis.

Transition-related outcomes among a cohort of patients with juvenile idiopathic arthritis.

Journal: Clinical rheumatology

Published: October 12, 2024

Sjögren's disease and systemic lupus erythematosus overlap syndrome as distinct entity at crossroads of two autoimmune disorders: clinical characterisation from two Italian reference centres for both the diseases.

Sjögren's disease and systemic lupus erythematosus overlap syndrome as distinct entity at crossroads of two autoimmune disorders: clinical characterisation from two Italian reference centres for both the diseases.

Journal: Clinical and experimental rheumatology

Published: September 24, 2024

Ultrasound-guided core needle biopsy of deep fascia: A cadaveric study evaluating feasibility, accuracy and reliability.

Ultrasound-guided core needle biopsy of deep fascia: A cadaveric study evaluating feasibility, accuracy and reliability.

Journal: Clinical anatomy (New York, N.Y.)

Published: July 24, 2024

Sicca manifestations and lymphoproliferation in hepatitis C virus: effects of direct acting antiviral therapy on dryness and B-cell activity compared to Sjögren's disease.

Sicca manifestations and lymphoproliferation in hepatitis C virus: effects of direct acting antiviral therapy on dryness and B-cell activity compared to Sjögren's disease.

Journal: Arthritis research & therapy

Published: June 30, 2024

The Challenge of IBD-Related Arthritis Screening Questionnaires in Early and Predominantly Entheseal Phenotypes.

The Challenge of IBD-Related Arthritis Screening Questionnaires in Early and Predominantly Entheseal Phenotypes.

Journal: Rheumatology and therapy

Published: April 10, 2024

Identification and evolution of predictors of Sjögren's disease-associated mucosa-associated lymphoid tissue lymphoma development over time: a case-control study.

Identification and evolution of predictors of Sjögren's disease-associated mucosa-associated lymphoid tissue lymphoma development over time: a case-control study.

Journal: The Lancet. Rheumatology

Published: April 03, 2024

Risk of developing psoriatic arthritis in psoriasis cohorts with arthralgia: exploring the subclinical psoriatic arthritis stage.

Risk of developing psoriatic arthritis in psoriasis cohorts with arthralgia: exploring the subclinical psoriatic arthritis stage.

Journal: RMD open

Published: March 07, 2024

The impact of two different rituximab-based strategies in cryoglobulinaemic vasculitis secondary to Sjögren's disease: a monocentric cohort study.

The impact of two different rituximab-based strategies in cryoglobulinaemic vasculitis secondary to Sjögren's disease: a monocentric cohort study.

Journal: Clinical and experimental rheumatology

Published: March 02, 2024

Safety and Efficacy of Ianalumab in Patients With Sjögren's Disease: 52-Week Results From a Randomized, Placebo-Controlled, Phase 2b Dose-Ranging Study.

Safety and Efficacy of Ianalumab in Patients With Sjögren's Disease: 52-Week Results From a Randomized, Placebo-Controlled, Phase 2b Dose-Ranging Study.

Journal: Arthritis & rheumatology (Hoboken, N.J.)

Published: February 07, 2024

Showing 1-12 of 235

Last Updated: 09/26/2026